Abstract 17501: Incremental Value of Combined Left Ventricular Volume and Matrix Metalloproteinase-2 for Risk Stratification of Patients with Non-Ischemic Dilated Cardiomyopathy
Background: Extracellular matrix remodeling and apoptosis are known to play important roles in the progression of heart failure (HF). The aim of this study was to evaluate the prognostic value of serum levels of matrix metalloproteinase(MMP)-2, MMP-3, soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with non-ischemic dilated cardiomyopathy (DCM).
Methods: Serum samples were obtained from 70 patients with DCM and analyzed for MMP-2, MMP-3, sFas and sFasL. Patients were followed up for the occurrence of either mortality or hospitalizations due to HF.
Results: Cardiac events were occurred at 21(30%) patients (death: 10, hospitalization due to HF: 11). LV end-diastolic volume (LVEDV) and end-systolic volume (LVESV) were higher and mitral Ea was lower in cardiac event group. Serum level of MMP-2 was significantly higher in cardiac event group (287.2±99.3 vs 221.0±68.9 ng/mL, p=0.01). However, serum levels of MMP-3, sFas and sFasL were not different between two groups. Kaplan-Meier event free survival curve stratified into 4 groups according to combinations of LVEDV and MMP-2 showed significantly different event rates (Fig 1). Cox proportional hazards analysis demonstrated that MMP-2 added significant incremental prognostic information (Fig 2).
Conclusion: Serum level of MMP-2, but not MMP-3, sFas or sFasL is an independent prognostic factor and combined LVV and MMP-2 have incremental value to predict cardiac events in patients with DCM.
- © 2011 by American Heart Association, Inc.